Science 37 Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial
Operating System™, and Syapse®, a leading real-world evidence
company, today announced a partnership to deploy proprietary
real-world data intelligence and analytics that will help identify
suitable patients for oncology clinical trials—ultimately speeding
up the enrollment process.
Study sponsors are increasingly looking outside of traditional
academic sites to source specific patient populations, but without
the data to pinpoint patients’ locations, recruitment can be
extremely challenging. Research indicates that roughly four in five
of all clinical trials are subject to delays1, most of which occur
at the enrollment stage. Not only are these delays problematic for
patients who are waiting to access potentially life-saving oncology
treatments, but they also can cost sponsors upwards of $20 million
per month in combined expenses and lost revenues.
“We are constantly exploring for faster, more efficient ways to
bring new oncology treatments to patients who need them,” said Dr.
Jonathan Cotliar, Chief Medical Officer, Science 37. “Recent
research shows that patient enrollment is the number one challenge
facing oncology research executives2. By partnering with Syapse, we
will have the ability to tap into advanced data-intelligence
capabilities to make effective trial identification and recruitment
a reality for patients and sponsors.”
To facilitate enrollment and reduce patient burden, oncology
research executives have begun to rely more on agile (hybrid) and
fully decentralized models.3
“The quality of treatments that health systems can deliver to
patients is directly linked to the quality of the clinical trials
conducted, which is why working with Science 37 is such a critical
opportunity,” said Ken Tarkoff, CEO of Syapse. “We are confident
that by combining Science 37’s agile capabilities with Syapse’s
ability to rapidly identify patients using real-world data, and the
oncology clinical trial expertise of Syapse’s health system
partners, this partnership will open the door to faster and more
effective recruitment in oncology research.”
There are already over 3,700 active oncology clinical trials
worldwide4, with research and development spending this year
projected to reach at least US$70 billion5—accounting for around
one-third of all drug R&D budgets in 20226. According to
projections, by 2026, there could be more than 10,500 oncology
clinical trials7.
About Science 37Science 37 Holdings, Inc.’s (Nasdaq: SNCE)
mission is to enable universal access to clinical research—making
it easier for patients and providers to participate from anywhere
and helping to accelerate the development of treatments that impact
patient lives. As a pioneer of decentralized clinical trials, the
Science 37 l Operating System (OS) supports today’s more agile
clinical research designs with its full-stack, end-to-end
technology platform and centralized networks of patient
communities, telemedicine investigators, mobile nurses, remote
coordinators, provider communities, and data and devices.
Configurable to enable almost any study type, the Science 37 OS
enables up to 21x faster enrollment, 28% better retention, and 3x
more diverse patient population with industry-leading workflow
orchestration, evidence generation, and data harmonization. For
more information, visit https://www.science37.com.
About Syapse Syapse is a company dedicated to extinguishing the
fear and burden of oncology and other serious diseases by advancing
real-world care. By marrying clinical expertise with smart
technologies, we transform data into evidence—and then into
experience—in collaboration with our network of partners, who are
committed to improving patients’ lives through community health
systems. Together, we connect comprehensive patient insights to our
network, to empower our partners in driving real impact and
improving access to high-quality care. For more information, visit
https://www.syapse.com
Sources1 Woolsey, B., Drug Development & Drug Delivery, Cost
of Disrupted Clinical Research Due to COVID-19 Equates to $10+
Billion & Potential Study Delays2, 3 Science 37, How Agile
Clinical Trials Are Impacting Oncology Research4, 5, 6, 7 Evaluate
Pharma
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains certain
forward-looking statements within the meaning of the federal
securities laws, including statements regarding the products
offered by Science 37, its sales pipeline and the markets in which
it operates, and Science 37’s anticipated growth and profitability.
These forward-looking statements generally are identified by the
words “believe,” “project,” “expect,” “anticipate,” “estimate,”
“intend,” “strategy,” “future,” “opportunity,” “plan,” “may,”
“should,” “will,” “would,” “will be,” “will continue,” “will likely
result” and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the ability to maintain the listing of Science 37’s
securities on Nasdaq, (ii) volatility in the price of Science 37’s
securities due to a variety of factors, including changes in the
competitive and highly regulated industries in which Science 37
operates, variations in performance across competitors, changes in
laws and regulations affecting Science 37’s business and changes in
its capital structure, (iii) the ability to implement business
plans, forecasts, and other expectations, and to identify and
realize additional opportunities, (iv) the risk that Science 37 may
never achieve or sustain profitability, (v) the risk that Science
37 will need to raise additional capital to execute its business
plan, which may not be available on acceptable terms or at all, and
(vi) the potential adverse effects of the ongoing global COVID-19
pandemic. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the “Risk Factors” section of our
Annual Report on Form 10-K for the fiscal year ended
December 31, 2021 filed with the U.S. Securities and Exchange
Commission (the “SEC”) on March 22, 2022 and in our other documents
filed by Science 37 from time to time with the SEC. These filings
identify and address other important risks and uncertainties that
could cause actual events and results to differ materially from
those contained in the forward-looking statements. Forward-looking
statements speak only as of the date they are made. Readers are
cautioned not to put undue reliance on forward-looking statements,
and Science 37 assumes no obligation and does not intend to update
or revise these forward-looking statements, whether as a result of
new information, future events, or otherwise, except as required by
law. Science 37 does not give any assurance that Science 37 will
achieve its expectations.
MEDIA INQUIRIES:Drew BustosScience
37PR@science37.com
INVESTOR RELATIONS:Caroline PaulScience 37 //
GilmartinInvestors@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Apr 2023 to Apr 2024